Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 13/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25356354 | 0.87 | NLRP3 (0.64) | NLRP3POLBPDGFRACDK5TYRO3 | |
| SCHEMBL25431544 | 0.85 | NLRP3 (0.59) | NLRP3POLBMEN1KMT2ATYRO3 | |
| SCHEMBL25356861 | 0.84 | NLRP3 (0.57) | NLRP3POLBPDGFRACDK5TYRO3 | |
| SCHEMBL29492084 | 0.82 | POLB (0.48) | NLRP3POLBAKR1B1PTGDR2 | |
| SCHEMBL29494684 | 0.81 | MAPT (0.50) | NLRP3AKR1B1MEN1CYP1A2CYP2C9 | |
| SCHEMBL29492036 | 0.79 | NLRP3 (1.00) | NLRP3 | |
| SCHEMBL29494685 | 0.79 | NLRP3 (0.52) | NLRP3POLBPDGFRACDK5TYRO3 | |
| SCHEMBL25356370 | 0.78 | NLRP3 (0.53) | NLRP3PDGFRACDK5TYRO3EGLN1 | |
| SCHEMBL498685 | 0.76 | NLRP3 (0.46) | NLRP3PDGFRACDK5TYRO3EGLN1 | |
| SCHEMBL25360566 | 0.76 | NLRP3 (0.48) | NLRP3MEN1KMT2APDGFRACDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4217346-B1 | NEW COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-02 | — | — | EP | disclosed |
| US-20230391756-A1 | NEW COMPOUND | JANSSEN PHARMACEUTICA NV (BE) | 2023-12-07 | — | — | US | disclosed |
| EP-4217346-A1 | NEW COMPOUNDS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022063876-A1 | NEW COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-31 | — | — | WO | disclosed |
| EP-3974415-A1 | NLRP3 MODULATORS | Janssen Pharmaceutica NV (BE) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391756-A1 | NEW COMPOUND | NLRP3, NLRP1, IL1R1 | NLRP3 1/4885POLB 2610/4885AKR1B1 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.